Skip Nav Destination
Issues
1 September 2001
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Editorials
Minireview
Review
Advances in Brief
Regular Articles
Clinical Trials
Virus-directed, Enzyme Prodrug Therapy with Nitroimidazole Reductase: A Phase I and Pharmacokinetic Study of its Prodrug, CB19541
Guy Chung-Faye; Daniel Palmer; David Anderson; Joanna Clark; Mandy Downes; Joanna Baddeley; Syed Hussain; Philip I. Murray; Peter Searle; Leonard Seymour; Peter A. Harris; David Ferry; David J. Kerr
Cancer Biology, Immunology, Cytokines
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Circulating HER-2/erbB-2/c-neu (HER-2) Extracellular Domain as a Prognostic Factor in Patients with Metastatic Breast Cancer: Cancer and Leukemia Group B Study 86621
Daniel F. Hayes; Hideko Yamauchi; Gloria Broadwater; Constance T. Cirrincione; Stephen P. Rodrigue; Donald A. Berry; Jerry Younger; Lawrence L. Panasci; Frederick Millard; David B. Duggan; Larry Norton; I. Craig Henderson
Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy1
Nadia Harbeck; Uta Alt; Ursula Berger; Achim Krüger; Christoph Thomssen; Fritz Jänicke; Heinz Höfler; Ronald E. Kates; Manfred Schmitt
Reduction of p12DOC-1 Expression Is a Negative Prognostic Indicator in Patients with Surgically Resected Oral Squamous Cell Carcinoma1
Satoru Shintani; Mariko Mihara; Nagaaki Terakado; Yuuji Nakahara; Tomohiro Matsumura; Yohko Kohno; Hiroe Ohyama; Jim McBride; Ralph Kent; Randy Todd; Takanori Tsuji; David T. W. Wong
The Early Growth Response Gene EGR-1 Behaves as a Suppressor Gene That Is Down-Regulated Independent of ARF/Mdm2 but not p53 Alterations in Fresh Human Gliomas1
Antonella Calogero; Antonietta Arcella; Giorgia De Gregorio; Antonio Porcellini; Dan Mercola; Chaoting Liu; Vincenza Lombari; Massimo Zani; Giuseppe Giannini; Franco Maria Gagliardi; Riccardo Caruso; Alberto Gulino; Luigi Frati; Giuseppe Ragona
Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5′-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU)- related Toxicity Compared with Controls1
Martin Raida; Wolfgang Schwabe; Peter Häusler; André B. P. Van Kuilenburg; Albert H. Van Gennip; Detlev Behnke; Klaus Höffken
Experimental Therapeutics, Preclinical Pharmacology
Treatment with Low-Dose Interferon-α Restores the Balance between Matrix Metalloproteinase-9 and E-Cadherin Expression in Human Transitional Cell Carcinoma of the Bladder1
Joel W. Slaton; Takashi Karashima; Paul Perrotte; Keiji Inoue; Sun J. Kim; Jonathan Izawa; Daniel Kedar; David J. McConkey; Randall Millikan; Paul Sweeney; Chiaki Yoshikawa; Taro Shuin; Colin P. N. Dinney
Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice1
Andrew M. Davidoff; Catherine Y. C. Ng; Peggy Brown; Margaret A. Leary; William W. Spurbeck; Junfang Zhou; Edwin Horwitz; Elio F. Vanin; Arthur W. Nienhuis
Role of the Raf Signal Transduction Cascade in the in Vitro Resistance to the Anticancer Drug Doxorubicin1
Caroline R. Weinstein-Oppenheimer; Carlos F. Henríquez-Roldán; Julianne M. Davis; Patrick M. Navolanic; Oussama A. Saleh; Linda S. Steelman; Richard A. Franklin; Penni J. Robinson; Martin McMahon; James A. McCubrey
Expression of β-Tubulin Isotypes in Human Ovarian Carcinoma Xenografts and in a Sub-Panel of Human Cancer Cell Lines from the NCI-Anticancer Drug Screen: Correlation with Sensitivity to Microtubule Active Agents1
Maria Ines Nicoletti; Giorgio Valoti; Paraskevi Giannakakou; Zhirong Zhan; Jon-Hyeok Kim; Valeria Lucchini; Fabio Landoni; Joseph G. Mayo; Raffaella Giavazzi; Tito Fojo
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.